MASS908 Devices Inc.

Revenue grew 23% to $16.1 million as adjusted EBITDA loss improved 50%.

908 Devices outlined its strategy to focus exclusively on handheld chemical and drug detection technologies for public safety and defense markets, following the divestiture of its life-sciences business line about 15 months ago. Speaking at a Canaccord Genuity event, President, CEO and Co-Founder K

908 Devices (NASDAQ:MASS) is sharpening its focus on handheld chemical and drug detection systems for public safety, defense and law enforcement following the divestiture of its bioprocessing and biopharma business line, executives said during a Canaccord Genuity discussion. Chief Executive Officer

908 Devices Inc (MASS) delivered 23% revenue growth in Q2 2026, driven by robust demand and strategic acquisitions, while improving profitability and raising full-year guidance.

Moby summary of 908 Devices Inc.'s Q2 2026 earnings call

908 Devices (NASDAQ:MASS) reported second-quarter revenue growth of 23% as demand from U.S. state and local government customers, FTIR product shipments and its recently acquired NIRLab platform supported results. The company also raised the low end of its full-year revenue outlook while continuing

908 Devices (MASS) delivered earnings and revenue surprises of +21.43% and +5.92%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Tactile Systems Technology (TCMD) delivered earnings and revenue surprises of +142.86% and +0.19%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Rapid Micro Biosystems (RPID) delivered earnings and revenue surprises of -3.85% and +3.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Delcath Systems (DCTH) delivered earnings and revenue surprises of +143.75% and +15.88%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

PROCEPT BIOROBO (PRCT) delivered earnings and revenue surprises of -2.17% and +2.16%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

908 Devices (MASS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.